The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China

BACKGROUND: Niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for first/second-line maintenance treatment of ovarian cancer patients with complete or partial response to platinum-based chemotherapy, and multi-line monotherapy in BRCAmt patients or platinum-sensitive recurrence...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jing, Cheng, Xianzhong, Zhao, Qian, Dai, Zhiqin, Xu, Xia, Guo, Wenwen, Gu, Hongyuan, Zhou, Rui, Wang, Yan, Chen, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127179/
https://www.ncbi.nlm.nih.gov/pubmed/33993885
http://dx.doi.org/10.1186/s13048-021-00803-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127179/
https://www.ncbi.nlm.nih.gov/pubmed/33993885
http://dx.doi.org/10.1186/s13048-021-00803-2

Ejemplares similares